Literature DB >> 26151618

Stereotactic body radiotherapy for central lung tumours: Author reply.

S Adebahr1,2, S Collette3, E Shash3, M Lambrecht4, C Le Pechoux5, C Faivre-Finn6, D De Ruysscher7, H Peulen8, J Belderbos8, R Dziadziuszko9, C Fink10, M Guckenberger11, C Hurkmans4, U Nestle1,2.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26151618      PMCID： PMC4743584          DOI： 10.1259/bjr.20150532

Source DB:  PubMed          Journal:  Br J Radiol        ISSN： 0007-1285            Impact factor:   3.039


× No keyword cloud information.
  4 in total

1.  LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective.

Authors:  S Adebahr; S Collette; E Shash; M Lambrecht; C Le Pechoux; C Faivre-Finn; D De Ruysscher; H Peulen; J Belderbos; R Dziadziuszko; C Fink; M Guckenberger; C Hurkmans; U Nestle
Journal:  Br J Radiol       Date:  2015-04-15       Impact factor: 3.039

2.  Stereotactic body radiotherapy for central lung tumours.

Authors:  M Dahele; H Tekatli; S Senan
Journal:  Br J Radiol       Date:  2015-07-07       Impact factor: 3.039

3.  Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors.

Authors:  Aadel A Chaudhuri; Chad Tang; Michael S Binkley; Michelle Jin; Jacob F Wynne; Rie von Eyben; Wendy Y Hara; Nicholas Trakul; Billy W Loo; Maximilian Diehn
Journal:  Lung Cancer       Date:  2015-05-04       Impact factor: 5.705

4.  Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer.

Authors:  Cornelis J A Haasbeek; Frank J Lagerwaard; Ben J Slotman; Suresh Senan
Journal:  J Thorac Oncol       Date:  2011-12       Impact factor: 15.609
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.